PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33183460-7 2021 After 24 hours of administration, the data shows that simvastatin-NLCs inhibit the levels of IL-6 and TNF-alpha inflammatory factor in the lungs of mice. Simvastatin 54-65 tumor necrosis factor Mus musculus 102-111 15777746-8 2005 The results suggest that simvastatin inhibits the formation of TNF-alpha and peroxynitrite in activated microglia thereby protecting dopaminergic neurons from inflammatory damage. Simvastatin 25-36 tumor necrosis factor Mus musculus 63-72 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 tumor necrosis factor Mus musculus 272-293 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 tumor necrosis factor Mus musculus 295-298 35618653-7 2022 They greatly inhibited the M1-type polarization of macrophages; reduced intracellular reactive oxygen species level and inflammatory cytokine; and TNF-alpha, MCP-1, and IL-1beta were secreted by macrophage cells, thus providing enhanced anti-inflammatory and antioxidant effects compared with free simvastatin. Simvastatin 298-309 tumor necrosis factor Mus musculus 147-156 26824358-0 2016 Correction: Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 12-23 tumor necrosis factor Mus musculus 162-189 32016638-10 2020 Simvastatin reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice. Simvastatin 0-11 tumor necrosis factor Mus musculus 108-117 32016638-12 2020 These findings suggest that reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice may be one of the mechanisms that simvastatin improves cognitive functions, depression, and anxiety in MPTP-lesioned mice. Simvastatin 189-200 tumor necrosis factor Mus musculus 124-133 32387414-10 2020 These data are consistent with simvastatin promoting alterations in peripheral febrigenic signaling (plasma levels of TNF-alpha, IL-1beta, and IL-10). Simvastatin 31-42 tumor necrosis factor Mus musculus 118-127 30699879-8 2019 Moreover, simvastatin markedly prevented and ameliorated LPS and CMS-induced neuroinflammation, as shown by the suppressed activation of microglia in hippocampus and decreased hippocampal pro-inflammatory cytokines expressions including IL-1beta, TNF-alpha, IL-6, which might be mediated via the inhibition of NF-kappaB pathway, as shown by the decreased nuclear NF-kappaB p65 expression. Simvastatin 10-21 tumor necrosis factor Mus musculus 247-256 31949780-10 2018 We found that simvastatin treatment could significantly inhibit inflammation by modulating the expression of mediators, such as IL-1beta, TNF-alpha and IL-6, whose expression were increased remarkably in the activated RAW264.7 cells. Simvastatin 14-25 tumor necrosis factor Mus musculus 138-147 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 46-57 tumor necrosis factor Mus musculus 318-321 29421861-9 2018 Simvastatin also reduced the serum cytokine levels and transcriptional levels of tumor necrosis factor-alpha and interleukin-6 in the liver. Simvastatin 0-11 tumor necrosis factor Mus musculus 81-108 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 tumor necrosis factor Mus musculus 221-230 24950285-0 2015 Simvastatin reduces burn injury-induced splenic apoptosis via downregulation of the TNF-alpha/NF-kappaB pathway. Simvastatin 0-11 tumor necrosis factor Mus musculus 84-93 26625143-0 2015 Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 0-11 tumor necrosis factor Mus musculus 150-177 24950285-9 2015 Simvastatin decreased burn-induced TNF-alpha and NF-kappaB expression in the spleen and serum. Simvastatin 0-11 tumor necrosis factor Mus musculus 35-44 24950285-12 2015 CONCLUSIONS: Simvastatin reduces burn-induced splenic apoptosis via downregulation of the TNF-alpha/NF-kappaB pathway. Simvastatin 13-24 tumor necrosis factor Mus musculus 90-99 25848815-16 2015 There was a 3-fold increase in plasma Tumor Necrosis Factor-alpha, a 7-fold increase in plasma Interleukin-6 and a 20-fold increase in lavage fluid Matrix-Metalloprotease-9 by HVt but simvastatin reduced these levels to control. Simvastatin 184-195 tumor necrosis factor Mus musculus 38-65 24040034-4 2013 The lipophilic statins, fluvastatin and simvastatin, reversed LPS-induced downregulation of CD9 and CD81, simultaneously preventing TNF-alpha and matrix metalloproteinase-9 production and spreading of RAW264.7 cells. Simvastatin 40-51 tumor necrosis factor Mus musculus 132-141 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 tumor necrosis factor Mus musculus 45-54 23275311-0 2013 Simvastatin protects hepatocytes from apoptosis by suppressing the TNF-alpha/caspase-3 signaling pathway in mice with burn injury. Simvastatin 0-11 tumor necrosis factor Mus musculus 67-76 23275311-6 2013 The effects of simvastatin on TNF-alpha and caspase-3 expressions were also evaluated in cultured mouse hepatocytes. Simvastatin 15-26 tumor necrosis factor Mus musculus 30-39 23275311-8 2013 Simvastatin reduced the apoptotic index in the livers of mice with burn injury and this effect could be abrogated by TNF-alpha or caspase-3 inhibitors. Simvastatin 0-11 tumor necrosis factor Mus musculus 117-126 23275311-9 2013 Simvastatin also decreased burn-induced TNF-alpha and caspase-3 expression in the liver. Simvastatin 0-11 tumor necrosis factor Mus musculus 40-49 23275311-11 2013 An in vitro study demonstrated that simvastatin suppresses TNF-alpha and caspase-3 expression in primary cultures of mouse hepatocytes. Simvastatin 36-47 tumor necrosis factor Mus musculus 59-68 23275311-12 2013 CONCLUSIONS: Simvastatin reduces mouse hepatocyte apoptosis by suppressing expression of the TNF-alpha/caspase-3 pathway. Simvastatin 13-24 tumor necrosis factor Mus musculus 93-102 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 79-106 23290865-6 2013 Both simvastatin and lovastatin suppressed IEL production of IFN-gamma, TNF-alpha, IL-2, and IL-4 in a dose-dependent manner, whereas 48-h treatment with high concentrations (5 x 10(-5)M) of simvastatin and lovastatin did not affect the number of IELs. Simvastatin 5-16 tumor necrosis factor Mus musculus 72-81 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 108-117 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 171-180 22102723-10 2012 Blockade of apoptosis by a pan-caspase inhibitor or by simvastatin sharply reduced the release of TNF-alpha but enhanced IL-10. Simvastatin 55-66 tumor necrosis factor Mus musculus 98-107 19631345-10 2010 LPS-provoked serum levels of TNF-alpha were decreased by 83% in hepatectomized animals treated with simvastatin. Simvastatin 100-111 tumor necrosis factor Mus musculus 29-38 19631345-11 2010 TNF-alpha-induced leukocyte adhesion as well as P-selectin expression in endothelial cells and LFA-1 function were inhibited by simvastatin in vitro. Simvastatin 128-139 tumor necrosis factor Mus musculus 0-9 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 13-24 tumor necrosis factor Mus musculus 52-61 19730988-0 2010 Simvastatin attenuates TNF-alpha-induced growth inhibition and apoptosis in murine osteoblastic MC3T3-E1 cells. Simvastatin 0-11 tumor necrosis factor Mus musculus 23-32 18310456-0 2008 Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. Simvastatin 0-11 tumor necrosis factor Mus musculus 24-51 18310456-5 2008 Simvastatin had no independent effects on Runx2 and alkaline phosphatase activity; however, it reversed the suppressive effects of TNF-alpha. Simvastatin 0-11 tumor necrosis factor Mus musculus 131-140 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 15-26 tumor necrosis factor Mus musculus 38-47 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 181-192 tumor necrosis factor Mus musculus 38-47 18310456-7 2008 In addition, cDNA array analysis revealed that simvastatin increased expression levels of Smads in C2C12 cells exposed to TNF-alpha that also activated mitogen-activated protein kinase (MAPK) signaling pathways, including extracellular signal-regulated kinase 1/2 (ERK1/2), P38, and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK). Simvastatin 47-58 tumor necrosis factor Mus musculus 122-131 18981156-10 2008 Administration of simvastatin in vivo stimulated endothelial SR-BI expression, which was accompanied by the inhibition of the ex vivo monocyte adhesion in aortas from TNF alpha-injected mice. Simvastatin 18-29 tumor necrosis factor Mus musculus 167-176 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Simvastatin 189-200 tumor necrosis factor Mus musculus 96-123 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Simvastatin 189-200 tumor necrosis factor Mus musculus 125-134 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 tumor necrosis factor Mus musculus 32-41 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 tumor necrosis factor Mus musculus 103-112 18310456-9 2008 Farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) reversed the simvastatin effects on TNF-alpha-induced activation of Ras/Rho/MAPK pathways. Simvastatin 82-93 tumor necrosis factor Mus musculus 105-114 18310456-10 2008 FPP and GGPP also restored the simvastatin effects on TNF-alpha-induced suppression of Runx2 and ALP activity. Simvastatin 31-42 tumor necrosis factor Mus musculus 54-63 18310456-12 2008 Collectively, simvastatin supports BMP-induced osteoblast differentiation through antagonizing TNF-alpha-to-Ras/Rho/MAPK pathway and augmenting BMP-Smad signaling, suggesting a potential usage of statins to ameliorate inflammatory bone damage. Simvastatin 14-25 tumor necrosis factor Mus musculus 95-104 18504409-7 2008 RESULTS: Incubation of BMMCs with simvastatin resulted in the inhibition of LPS-induced TNF-alpha production at both mRNA and protein levels. Simvastatin 34-45 tumor necrosis factor Mus musculus 88-97 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 225-236 tumor necrosis factor Mus musculus 52-61 16321392-6 2006 First, we have shown by ELISA that 1 microM simvastatin significantly reduced MCP-1 in endothelial cells (ECs) and macrophages stimulated with TNF-alpha or IFN-gamma, respectively. Simvastatin 44-55 tumor necrosis factor Mus musculus 143-152 17178392-4 2007 Simvastatin (50 micro M) significantly inhibited TNF-alpha-induced IL-8 gene expression in COLO 205 cells. Simvastatin 0-11 tumor necrosis factor Mus musculus 49-58 17178392-5 2007 Simvastatin (50 micro M) blocked TNF-alpha-induced NF-kappaB transcriptional activity, IkappaB phosphorylation/degradation and DNA binding activity of NF-kappaB. Simvastatin 0-11 tumor necrosis factor Mus musculus 33-42